||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Ixico Share Discussion Threads
Showing 126 to 146 of 150 messages
|Now the CEO is on a nice jolly to Washington DC. Shame the shares are plummeting - it's like phytopharm all over again....|
|A very depressing share this one!|
|Very quiet on here. Seems like a good little company with excellent growth prospects too. Anyone else around with a view? Cheers|
|Why is it plummeting like this? Any bad news?|
|it wants to go above 40p. what will drive it I wonder|
|More good news|
|Under the radar and going strong-should soon be in profit and could well jump to the analyst 67p level sometime soon,tucked away a few late last year.|
18 January 2016
IXICO awarded four contracts worth a combined value of over GBP3.0m
Further cements IXICO's partnerships with leading pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease.
18 January 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has recently been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over GBP3.0m.
The contracts are for global clinical trials of novel drugs for Alzheimer's disease which span the three major phases of drug development and are expected to run for the next two to four years, subject to the drugs successfully progressing through the clinical trials process. They will utilise IXICO's expertise in the Alzheimer's field and our proprietary TrialTracker(R) and Assessa(R) digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.
The award of these contracts builds on IXICO's expertise in brain health following a long term contract for a Phase II/III global study in neurodegenerative disease and selection as the imaging analysis partner within The European Prevention of Alzheimer's Dementia Initiative (EPAD), announced in 2015.
Professor Derek Hill, Chief Executive Officer of IXICO, commented: "We are very pleased to have been awarded these significant projects. Not only do they validate the value our digital platforms provide, but also highlight the strength of IXICO's relationships with pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease. The revenues from these contracts augment the board's confidence in meeting market expectations."|
|IXI Being bought a bit this morning and up to almost the full ask of 35p.
Stock still extremely tight here with only 7k showing at each side of the bid/ask. Those 7k on the ask run all the way up to 48p being asked for the last 1000 shrs.
It's almost impossible for IXI not to see a major uptick if even modest concerted buying is seen.
Well worth pinning some down whilst the share price is more than reasonable, imo.
|Clinical trial contract award raising the bar
IXICO has secured one of its biggest contracts yet, worth $7m over seven years for clinical trial services. The award supports our investment thesis and financial forecasts, reflecting strong growth through the expansion into new indications, new markets and bigger contracts. IXICO is also well placed to capitalise on the burgeoning use of digital technologies in disease management. Using a DCF, we value IXICO at £10.7m or 63p/share.
|Very low mkt cap...sub £5m. Ive taken a few more in the last couple of days.
|IXICO awarded significant long-term contract
IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announced that it has been awarded a long-term contract from a leading global pharmaceutical company with a revenue value to IXICO of c. $1 million per year.
|What's going on here? Shares in Ixico going up? How unusual, they normally go down . Does someone know something ?|
|IXI well in demand today.... + 8.8%.
Precious little stock showing on Level 2....just 7k shrs each side of the bid/ask, all spread over 4 mm's, some of whom show only 1000 shrs.
Easy to see how any strong whiff of demand will quickly send IXI much higher.
The best ask is now shown at 33p.
|Award of Two New Clinical Trial Contracts - in Oncology and Neurodegenerative Disease
29 June 2015, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announced that together with its alliance partner, VirtualScopics, Inc. (Ticker: VSCP) ('VirtualScopics'), it has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumours and one in a rare neurodegenerative disease. IXICO's TrialTracker™ digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa® digital technology will be used to analyse MRI data collected from patients.
The metastatic solid tumour study will make use of VirtualScopics extensive expertise applying FDG-PET (Fludeoxyglucose PET) to measuring disease progression in oncology and will involve working with imaging centres across North America and Europe. The study is expected to complete in June 2017.
The neurodegeneration study will make use of IXICO's expertise in structural MRI and will involve IXICO working with key opinion leaders across specialist imaging centres throughout North America. As part of this contract, IXICO's Assessa® medical device will utilise its proprietary LEAP methodology to quantify disease pathology in brain regions that are particularly relevant to measuring disease progression and will be applied to MRI data collected from subjects enrolled in the study. The study is expected to complete in January 2018.
Professor Derek Hill, Chief Executive Officer of IXICO, commented: "Our alliance with VirtualScopics continues to be valued by our pharmaceutical partners as we support their clinical trials on a global basis, as evidenced by these two new contract wins. Our TrialTracker™ digital platform provides customers with digital technology combined with operational effectiveness. Furthermore, our involvement with the neurodegenerative disease study demonstrates our ability to broaden our therapeutic expertise and validates the importance of IXICO's technology across a range of brain diseases."
Eric Converse, Chief Executive Officer of VirtualScopics commented: "Winning these two recent studies with IXICO clearly demonstrates the strength of our alliance. We are bringing a viable, stronger imaging choice to the risk averse pharmaceutical industry. The list of studies on TrialTracker™ within VirtualScopics continues to grow with increased momentum. Customers are very pleased with this option. TrialTracker™ is the backbone of our relationship with IXICO and allows us to fully exploit our collaborative offering."|
|18/05/2015 07:01 UKREG IXICO plc Interim Results
" ... During the six months there was a net cash outflow of GBP1.3million resulting in a cash position of GBP1.95million at 31 March 2015 (H1 2014: GBP3.89million). ... "
At the current rate of cashburn the cash won't last another year.
This suggests the likelihood of a fundraising at a lower level than the current 26.5p.|
|And the price continues to drop like a brick, think it's about time to get rid of this one. Have had enough|
|Half Yearly Report to 31 March 2015
Expanding clinical trials services and digital healthcare offering
Strong growth in total income and reduction in loss
IXICO plc (AIM: IXI), the brain health company, announces its unaudited interim results for the six months ended 31 March 2015.
· Extension of two clinical trials in Huntington's Disease, valued at approximately £2.5m over three years
· VirtualScopics alliance delivering commercial value
o Won first joint project for top 15 pharmaceutical company
o License of TrialTracker™ proprietary image data and query management platform
· Partner in the European Prevention of Alzheimer's dementia Initiative (EPAD)
· Strengthened capabilities, technology and IP on healthcare data analytics
· Financial performance underpinned by strong revenue growth of 36% to £1.6m
o Total income (revenue plus other income) up 40% to £2.0m
o Loss reduced by 58% to £0.6m despite increased investment in R&D; Loss per share 4.1p (2014 loss per share 10.5p)
o Cash of £1.95m at 31 March 2015 with second half cash inflows to include committed grant funding
· Third contract award in Huntington's Disease within 12 months
· Launch of the Project Cygnus digital platform to support patients with the diseases that cause dementia
o IXICO is the lead partner working alongside The Northern Health Science Alliance Network, several NHS Trusts in the North of England and MRC Technology
· UK Government funded project to support accurate differential diagnosis of CNS diseases
Derek Hill, Chief Executive Officer of IXICO, said:
"We have delivered strong growth in our business and made good progress in executing important strategic developments during the period. Our digital technology platforms are opening up new, high value commercial opportunities with existing and new customers in dementia and increasingly, other diseases. The marked top-line growth we have reported arises from both expansion of our clinical trials business and initial contracts from the pharmaceutical sector for our digital healthcare platform. We expect to maintain this momentum and to grow our digital healthcare revenue moving forward.
We look forward to building on this progress to take IXICO into the next phase of its corporate development. We continue to explore opportunities to build critical mass through further partnerships, product licencing and potential merger and acquisition activities."|
|Thanks Hedgehog, yes I meant the finals. IXI seems to be flatlining now. An interesting space but hard to value! Thanks for the link.|